[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408353":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":61,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":25,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":25,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":25,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tamsulosin","EXPERIMENTAL","10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.\n\nBoth study drug and placebo will appear identical and will be prepared by the pharmacy.",[13],"Drug: Tamsulosin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.\n\nBoth study drug and placebo will appear identical and will be prepared by the pharmacy.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.",[15],[30],{"name":31,"affiliation":5,"role":32},"Lindsay Turner, MD","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Lindsay Turner","CONTACT","(412)-330-4567","lindsay.turner@AHN.ORG",{"name":40,"role":36,"phone":37,"phoneExt":25,"email":41},"AHN Clinical Trials Contact","clinicaltrials@ahn.org",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"West Penn Hospital","RECRUITING","Pittsburgh","Pennsylvania","15224","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-79.99589,40.44062,{"lat":55,"lon":54},[58,60],{"name":40,"role":36,"phone":59,"phoneExt":25,"email":41},"(412)-330-6151",{"name":31,"role":32,"phone":25,"phoneExt":25,"email":25},{"type":32,"investigatorFullName":35,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Director of Urogynecology, Principal Investigator",[64],{"name":65,"class":6},"Johns Hopkins University","100408353","phase-2-impact-of-tamsulosin-on-post-operative-urinary-retention-following-pelvic-reconstructive-surgery-100408353",false,"NCT04597372","Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery","The Impact of Tamsulosin on Duration of Post-Operative Urinary Retention in Women Undergoing Pelvic Reconstructive Surgery- A Double Blind, Randomized, Placebo-Controlled Study","Inclusion Criteria:\n\n* 18 years or older\n* willing and able to provide informed consent\n* postoperative urinary retention as defined by a failed RGVT prior to hospital discharge\n* Ability to speak and read English\n* Tolerate pill ingestion\n\nExclusion Criteria:\n\n* allergy\u002Fintolerance to Tamsulosin or sulfa drugs\n* preoperative history of urinary retention as defined by preoperative post void residual of \\>150mL\n* current use of alpha antagonist medication for hypertension\n* severe dementia\n* end stage renal or liver disease\n* history of severe heart failure or major cardiovascular event in the last 6 months",true,"FEMALE","18 Years",{"count":77,"type":78},154,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The objective of the study is to determine the effectiveness of postoperative Tamsulosin in reducing the duration of acute postoperative urinary retention (POUR) following pelvic reconstructive surgery through a double blind, randomized placebo-controlled trial.",[84],"Urinary Retention Postoperative","2026-03-18",{"date":87,"type":88},"2026-03-20","ACTUAL",{"date":90,"type":88},"2021-11-03",{"date":92,"type":78},"2026-12",{"name":5,"class":6},1]